Stockreport

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda [Yahoo! Finance]

HUTCHMED (China) Limited - American Depositary Shares  (HCM) 
NASDAQ:AMEX Investor Relations: chi-med.com/investors/information-for-shareholders
PDF — FRUZAQLA ® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG [Read more]